IUC26691-89

Abstract Code: IUC26691-89   Real-World Outcomes of Delayed Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Following Systemic Therapy: A Tertiary Centre Experience M. Hassan 1 , H. Warren 1 , R. Nair 1 , D. Crawley 1 , A. Khan 1 , A. Fernando 1 , T....

IUC26690-88

Abstract Code: IUC26690-88   Cannabinoid Receptor Profiling Reveals a Low CB1 and High CB2 signature in Clear Cell Renal Cell Carcinoma S. Singh 1, S. Pattanaik 2, R.S. Mavuduru 2, N. Kakkar 2, G.S. Bora 2 (1) PhD, Post-Graduate Institute of Medical Education and...

IUC26686-93

Abstract Code: IUC26686-93   Synergistic potential of cabozantinib and radiotherapy in advanced renal cell carcinoma by site of irradiation F. Di Costanzo 1, A. Bertocchi 2, M.L. Esposito 3, I.S. Parisi 4, A. Federico 2, P.A. Zucali 2, L. Formisano 3, C. Oing 1,...

IUC26682-89

Abstract Code: IUC26682-89   Efficacy and tolerability of immune checkpoint inhibitors in older versus younger patients with metastatic renal cell carcinoma: a real-world Asian cohort R. Kanesvaran 1, H.S. Tan 1, J.W.K. Chan 1, W.C. Tan 1, D.J.M. Ang 1, J.J.X....

IUC26678-94

Abstract Code: IUC26678-94   Impact of Metastatic Patterns on First-Line Therapy in mRCC: Meet-URO 33 E. Peretto 1, S.E. Rebuzzi 2, E. Verzoni 3, S. Buti 4, M. Di Napoli 5, C. Lolli 6, M. Fanelli 7, C. Masini 8, P.A. Zucali 9, A. Mennitto 10, M. Sorarù 11, R....

IUC26672-88

Abstract Code: IUC26672-88   Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33) D. Aspden 1, D. Bimbatti 2, A. Dalla Volta 3, G. Roviello 4, R. Iacovelli 5, G. Bozza 6, M.G. Vitale 7, E. Fantinel 8, A. Guida 9, F.M....
error: Content is protected !!